|Novavax Reports Two Highest Doses in Trial of Vaccine Using Matrix-M Showed Statistical Significant Reductions|
|By Staff and Wire Reports|
|Friday, 13 September 2013 18:49|
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company creating novel recombinant nanoparticle vaccines and vaccine adjuvants, reported its partner, Genocea Biosciences Inc., announced positive, interim topline data from a Phase 1/2A clinical trial of its lead candidate, GEN-003, a first-in-class investigational protein subunit vaccine for patients with moderate-to-severe herpes simplex virus type 2 (HSV-2) infection. Genocea's herpes simplex virus-2 therapeutic vaccine candidate uses the Novavax proprietary adjuvant known as Matrix-M.
Genocea's results showed that vaccination with GEN-003 potentiated by the Matrix-M adjuvant can significantly blunt HSV-2 infection and reduce viral shedding. The two highest dose cohorts, both adjuvanted with Matrix-M, demonstrated significant reductions in viral shedding (51% and 30%, respectively, each p<0.001). No serious adverse events were related to the vaccine.
The partnership agreement with Genocea covers the use of Matrix-M in the development of vaccines against specific diseases including herpes simplex virus type 2.
ActiveCare, Inc. (OTCBB:ACAR), the service leader in disease and diabetes management, today announced the opening of their new corporate headquarters. ActiveCare's new home is strategically located near two major universities providing a highly skilled and educated workforce.
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN), today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved the use of Soliris® (eculizumab) for the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS), a life-threatening ultra-rare disorder.
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that it has appointed Mr. F. Randall Grimes, MBA as Director of Sponsored Research.
Arrhythmia Research Technology Inc. (NYSE MKT: HRT) announced today that the Company's Board of Directors appointed Mr. Derek T. Welch, age 45, the Company's Corporate Controller, to act as principal financial officer and accounting officer of the Company upon the resignation, effective September 12, 2013, of Mr. David A. Garrison, who served as the Company's Executive Vice President and Chief Financial Officer.
Biocon Ltd, Asia's largest biotech company, and CytoSorbents Corporation (OTCQB: CTSO), based in the United States, announced today, World Sepsis Day, that they have entered into a strategic partnership with an initial distribution agreement for India and select emerging markets, under which Biocon will have the exclusive commercialization rights for CytoSorb®, a novel therapy for the management of sepsis.
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) today announced that it has agreed to sell 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC and an affiliate of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or placement agent for gross proceeds of approximately $15 million (the "Offering").
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) in connection with the previously announced merger agreement under which Cubist will acquire all of the outstanding common stock of Optimer.
EasyMed Services, Inc. (CNSX:EZM) (OTCBB:EMYSF) (MUN:EY6) is a global medical information technology company delivering an end-to-end patient care solution through mobile phone, PDA and server technologies.
Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company focused on developing and commercializing innovative, targeted oncology treatments to address major unmet medical needs to advance cancer care, announced today the pricing of an underwritten public offering of 17,500,000 units at a public offering price of $2.00 per unit, resulting in gross proceeds of $35,000,000.
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that it has agreed to a joint research and development initiative with Rentokil Initial PLC that may lead to a new generation of highly-effective and sustainable pest control product and solution.
Masimo (NASDAQ: MASI) today announced that Rochester General Health System and its 528-bed flagship Rochester General Hospital have installed the Masimo Patient SafetyNet™ system, a remote monitoring and clinician notification system shown to dramatically reduce rapid response activations, transfers to intensive care units, and deaths related to opioid-induced respiratory depression.
Nanosphere, Inc. (NASDAQ: NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today announced the pricing of its previously announced underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $1.75 per share.
NeoStem, Inc. (Nasdaq:NBS), an emerging leader in the fast growing cell therapy industry, today announced that it has been awarded funds for the second year of a two year grant totaling $1,221,854 for "Repair of Bone Defects with Human Autologous Pluripotent Very Small Embryonic-Like Stem Cells (VSEL)," from the National Institute of Dental & Craniofacial Research ("NIDCR"), a division of the National Institutes of Health ("NIH").
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company creating novel recombinant nanoparticle vaccines and vaccine adjuvants, today reported that its partner, Genocea Biosciences Inc., announced positive, interim topline data from a Phase 1/2A clinical trial of its lead candidate, GEN-003, a first-in-class investigational protein subunit vaccine for patients with moderate-to-severe herpes simplex virus type 2 (HSV-2) infection.
OPTIMIZERx Corp. (OTCQB: OPRX) today announced the launch of OPTIMIZEHR®the company's Electronic Heath Record (EHR) consulting and implementation practice.
PharmAthene, Inc. (NYSE MKT: PIP) announced today that new non-clinical animal data from the Company's SparVax®next-generation anthrax vaccine program were presented at the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Co. The data presented showed that immunization with SparVax® provides dose-dependent protection against lethal anthrax infection.
Provectus Pharmaceuticals, Inc. (OTCQB:PVCT), a development-stage oncology and dermatology biopharmaceutical company, has received U.S Patent No. 8,530,675 by the United States Patent and Trademark Office (USPTO), protecting the synthetic process used to produce the small molecule Rose Bengal, the active pharmaceutical ingredient (API) in PV-10, the Company’s lead oncology drug candidate.